Cigarette use and cardiovascular risk in chronic kidney disease: An unappreciated modifiable lifestyle risk factor

Seminars in Dialysis

Volumn 23, Issue 3, 2010, Pages 298-305

  Stack, Austin G ^a,b   Murthy, Bhamidipati V R ^b  

^a LETTERKENNY GENERAL HOSPITAL   (Ireland)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; HUMAN; INCIDENCE; LIFESTYLE; METHODOLOGY; PROGNOSIS; REVIEW; RISK FACTOR; SMOKING; SMOKING CESSATION; SURVIVAL RATE; CARDIOVASCULAR DISEASES; COMPLICATION; PROCEDURES; TRENDS;

CARDIOVASCULAR DISEASES; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; LIFE STYLE; PROGNOSIS; RISK FACTORS; SMOKING; SMOKING CESSATION; SURVIVAL RATE;

EID: 77955144771     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2010.00728.x     Document Type: Review

References (75)

1. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske RN, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998, 32:853-906.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32(Suppl 3):S112-S119.
3. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levey D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999, 56:2214-2219.
4. Stack AG, Bloembergen WE. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: A cross-sectional study. J Am Soc Nephrol 2001, 12:1516-1523.
5. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE study. J Am Soc Nephrol 2002, 13:1918-1927.
6. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 2001, 134:629-636.
7. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003, 41:47-55.
8. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001, 12:218-225.
9. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Cardiovascular disease risk status in elderly persons with renal insufficiency. Kidney Int 2002, 62:997-1004.
10. Reis SE, Olson MB, Fried L, Reeser V, Mankad S, Pepine CJ, Kerensky R, Merz CN, Sharaf BL, Sopko G, Rogers WJ, Holubkov R. Mild renal insufficiency is associated with angiographic coronary artery disease in women. Circulation 2002, 105:2826-2829.
11. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003, 63:1121-1129.
12. Friedman PJ. Serum creatinine: An independent predictor of survival after stroke. J Intern Med 1991, 229:175-179.
13. McCullough PA, Soman SS, Shah SS, Smith ST, Marks KR, Yee J, Borzak S. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 2000, 36:679-684.
14. Madore F. Uremia-related metabolic cardiac risk factors in chronic kidney disease. Semin Dial 2003, 16:148-156.
15. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004, 140:9-17.
16. Haffner SM, Gruber KK, Aldrete G, Morales PA, Stern MP, Tuttle KR. Increased lipoprotein (a) concentrations in chronic renal failure. J Am Soc Nephrol 1992, 3:1156-1162.
17. Stenvinkel P, Heimburger O, Tuck CH, Berglund L. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int 1998, 53:1336-1342.
18. Bostom AG, Shemin D, Lapane KL, Sutherland P, Nadeau MR, Wilson PW, Yoburn D, Bausserman L, Tofler G, Jacques PF, Selhub J, Rosenberg IH. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study. Atherosclerosis 1996, 125:91-101.
19. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003, 107:87-92.
20. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004, 65:1009-1016.
21. Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, Kronenberg F. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein (a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 1997, 8:1889-1898.
22. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R. The natural history of homocystinuria due to cystathionine B beta-synthase deficiency. Am J Hum Genet 1985, 37:1-31.
23. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, Dennis VW. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998, 97:138-141.
24. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, Dworkin L, Rosenberg IH. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study. Arterioscler Thromb Vasc Biol 1997, 17:2554-2558.
25. Jungers P, Chauveau P, Bandin O, Chadefaux B, Aupetit J, Labrunie M, Descamps-Latscha B, Kamoun P. Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients. Miner Electrolyte Metab 1997, 23:170-173.
26. Massy ZA, Chadefaux-Vekemans B, Chevalier A, Bade CA, Drueke TB, Legendre C, Lacour B, Kamoun P, Kreis H. Hyperhomocysteinemia: A significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1994, 9:1103-1108.
27. Freund KM, Belanger AJ, D'Agostino RB, Kannel WB. The health risks of smoking. The Framingham study: 34 years of follow-up. Ann Epidemiol 1993, 3:417-424.
28. Sytkowski PA, D'Agostino RB, Belanger A, Kannel WB. Sex and time trends in cardiovascular disease incidence and mortality: The Framingham heart study 1950-1989. Am J Epidemiol 1996, 143:338-350.
29. State-specific prevalence of current cigarette smoking among adults-United States, 2003. MMWR Morb Mortal Wkly Rep 2004, 53:1035-1037.
30. Cigarette smoking among adults - United States, 2007. MMWR Morb Mortal Wkly Rep 2008, 57:1221-1226.
31. Fiore MC, Jaén CR, Baker TB. Treating Tobacco Use and Dependence: 2008 Update. Quick Reference Guide for Clinicians 2009, Rockville, MD, U.S. Department of Health and Human Services. Public Health Service
32. Comorbid conditions and correlations with mortality risk among 3,399 incident hemodialysis patients. Am J Kidney Dis 1992, 20(Suppl 2):32-38.
33. Nguyen HT, Stack AG. Ethnic disparities in cardiovascular risk factors and coronary disease prevalence among individuals with chronic kidney disease: Findings from the Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2006, 17:1716-1723.
34. Foley RN, Herzog CA, Collins A. Smoking and outcomes in dialysis patients. The United States renal data system wave 2 study. Kidney Int 2003, 63:1462-1467.
35. Bloembergen WE, Stannard DC, Port FK, Wolfe RA, Pugh JA, Jones CA, Greer JW, Golper TA, Held PJ. Relationship of dose of hemodialysis and cause-specific mortality. Kidney Int 1996, 50:557-565.
36. Fishbane S, Youn S, Flaster E, Adam G, Maesaka JK. Ankle-Arm Blood Pressure Index as a predictor of mortality in hemodialysis patients. Am J Kidney Dis 1996, 27:668-672.
37. Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 2002, 61:2157-2164.
38. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B. Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. JAMA 2005, 293:1737-1745.
39. Schroeder SA. Tobacco control in the wake of the 1998 master settlement agreement. N Engl J Med 2004, 350:293-301.
40. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
41. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101:948-954.
42. Moncada S, Palmer R, Higgs E. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43:109-141.
43. Pestana IA, Vazquez-Padron RI, Aitouche A, Pham SM. Nicotinic and PDGF-receptor function are essential for nicotine-stimulated mitogenesis in human vascular smooth muscle cells. J Cell Biochem 2005, 96:986-995.
44. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, Tsao PS, Johnson FL, Cooke JP. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001, 7:833-839.
45. Bernhard D, Rossmann A, Henderson B, Kind M, Seubert A, Wick G. Increased serum cadmium and strontium levels in young smokers: Effects on arterial endothelial cell gene transcription. Arterioscler Thromb Vasc Biol 2006, 26:833-838.
46. Pinto-Sietsma SJ, Mulder J, Janssen WM, Hillege HL, de Zeeuw D, de Jong PE. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000, 133:585-591.
47. Regalado M, Yang S, Wesson DE. Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. Am J Kidney Dis 2000, 35:687-694.
48. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: A 10-year prospective observational study. Diabetes Care 2002, 25:859-864.
49. The Health Consequences of Smoking: A Report of the Surgeon General 2004, Washington, DC, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health
50. Schroeder SA. We can do better - improving the health of the American people. N Engl J Med 2007, 357:1221-1228.
51. Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Rosner B, Hunter DJ, Hennekens CH, Speizer FE. Smoking cessation in relation to total mortality rates in women: A prospective cohort study. Ann Intern Med 1993, 119:992-1000.
52. Taylor DH, Hasselblad V, Henley SJ, Thun MJ, Sloan FA. Benefits of smoking cessation for longevity. Am J Public Health 2002, 92:990-996.
53. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004, 328:1519-1528.
54. The Health Benefits of Smoking Cessation: A Report of the Surgeon General 1990, Washington, DC, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, DHHS Publication (CDC) 90-8416
55. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977, 1:1645-1648.
56. Lancaster T, Stead L, Silagy C, Sowden A. Effectiveness of interventions to help people stop smoking: Findings from the Cochrane Library. BMJ 2000, 321:355-358.
57. Corelli RL, Hudmon KS. Tobacco use and dependence. Applied Therapeutics: The Clinical Use of Drugs 2004, 85-1-85-29. Koda-Kimble MA, Young LYKradjan WAGuglielmo BJAlldredge BKCorelli RL. eds, 8th edn, Baltimore, Md, Lippincott Williams & Wilkins
58. Rigotti NA. Treatment of tobacco use and dependence. N Engl J Med 2002, 346:506-512.
59. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 10.1002/14651858.CD000146.pub3, 1: CD000146, 2009. DOI:
60. Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: Systematic review and meta-analysis. BMJ 2009, 338:b1024.
61. Hurt RD, Sachs DPL, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM. A comparison of sustained-release Bupropion and placebo for smoking cessation. N Engl J Med 1997, 337:1195-1202.
62. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB. A controlled trial of sustained-release Bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999, 340:685-691.
63. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 2006, 296:47-55.
64. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease. a randomized trial. Circulation 2010, 121:221-229.
65. U.S. Drug and Food Administration Alert (FDA): Information for Healthcare Professionals: Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics) http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm169986.htm, Available at, accessed on January 7, 2009
66. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev 10.1002/14651858.CD000058.pub2, 3:CD000058, 2004. DOI:
67. Hughes JR, Stead LF, Lancaster T. Nortriptyline for smoking cessation: A review. Nicotine Tob Res 2005, 7:491-499.
68. Kinnunen T, Doherty K, Militello FS, Garvey AJ. Depression and smoking cessation: Characteristics of depressed smokers and effects of nicotine replacement. J Consult Clin Psychol 1996, 64:791-798.
69. Chase HP, Garg SK, Marshall G, Berg CL, Harris S, Jackson WE, Hamman RE. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 1991, 265:614-617.
70. Sawicki PT, Didjurgeit U, Mühlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994, 17:126-131.
71. Molander L, Hansson A, Lunell E, Alainentalo L, Hoffmann M, Larsson R. Pharmacokinetics of nicotine in kidney failure. Clin Pharmacol Ther 2000, 68:250-260.
72. Hukkanen J, Jacob P, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev March 2005, 57:79-115.
73. Worrall SP, Almond MK, Dhillon S. Pharmacokinetics of Bupropion and its metabolites in haemodialysis patients who smoke: A single dose study. Nephron Clin Pract 2004, 97:c83-c89.
74. Schroeder AS. What to do with a patient who smokes? JAMA 2005, 294:482-487.
75. K/DOQI Clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005, 45(Suppl 3):1-154.